Clinical trials: Classical Hodgkin Lymphoma
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell…
- Conditions
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Trial name
- NCT05821088
- Testing
- Biopsy, Biospecimen Collection, Carboplatin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- David Bond, MD
Diffuse Large Cell Lymphoma, Lymphoblastic Lymphoma
Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients
The purpose of this study is to define if flow cytometry has more sensitivity for detecting neoplastic cells in cerebrospinal fluid versus conventional cytology.
- Conditions
- Diffuse Large Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma
- Trial name
- CFM (NCT00949741)
- Where
- 12 sites in Italy
- Volunteers
- 175 people
- Sponsor
- Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Hodgkin Lymphoma, Adult, Relapse
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Young patients with relapsed or refractory classic Hodgkin's lymphoma will be treated with PD-1 inhibitor combined with decitabine as second-line salvage treatment for four cycles.
- Conditions
- Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma
- Trial name
- NCT05137886
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
- Trial name
- NCT03200977
- Testing
- Non-Interventional
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
This phase III trial compares chemotherapy versus an immune checkpoint inhibitor drug called pembrolizumab plus chemotherapy in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or that does not…
- Trial name
- NCT05711628
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00369681
- Testing
- Bleomycin, Rituximab, Dacarbazine
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Cervical Cancer, Cervical Intraepithelial Neoplasia
HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN
To compare the effects of conventional cytology testing with concommitant HPV-cytology testing for the detection of high grade cervical lesions in primary cervical cancer screening in Hong Kong Hypotheses: 1.
- Trial name
- COCY (NCT01058460)
- Testing
- HPV-cytology co-testing
- Where
- China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
The aim of this multicenter, non-randomized, cluster controlled trial study is to evaluate the impact of a geriatric-guided approach with a pro-active rehabilitative/nutritional plan for elderly unfit/frail DLBCL patients…
- Trial name
- NCT07476105
- Testing
- Geriatric-guided supportive care, Conventional supportive care
- Where
- 24 sites in Italy
- Volunteers
- 170 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
CLASSICAL HODGKIN LYMPHOMA
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Phase I trial aimed to determine the Maximum Tolerable Dose of the BV in combination with ESHAP in relapsed/resistant Hodgkin Lymphona patients and to evaluate response to treatment with BV-ESHAP as salvage regimen prior to…
- Trial name
- NCT02243436
- Testing
- Brentuximab Vedotin, Etoposide, Soludomerin
- Where
- 14 sites in Spain
- Volunteers
- 67 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Relapsed/Refractory Classical Hodgkin Lymphoma
Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma
< STUDY DESIGN > This study is a multi-center phase II trial in patients with relapsed or refractory Hodgkin's lymphoma after first-line treatment. < Treatment Schedule > 1.
- Trial name
- NCT05243693
- Testing
- Brentuximab vedotin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, Korea
Classical Hodgkin Lymphoma
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
- Trial name
- NCT06617286
- Testing
- CD30 CAR T-cell
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- New York Medical College
Hodgkin Lymphoma
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
This is a study of pembrolizumab (MK-3475) for participants with relapsed/refractory classical Hodgkin Lymphoma (RRcHL) who: 1) have failed to achieve a response or progressed after autologous stem cell transplant (auto-SCT) and…
- Trial name
- NCT02453594
- Testing
- pembrolizumab
- Volunteers
- 211 people
- Sponsor
- Merck Sharp & Dohme LLC
Hodgkin Disease Lymphoma
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
This is an open-label, multicenter, randomized, phase 3 trial to evaluate the efficacy of Penpulimab vs. standard chemotherapy selected by investigator in patients with relapsed or refractory classic Hodgkin's lymphoma.
- Trial name
- NCT05244642
- Testing
- Penpulimab, Investigator's choice of Chemotherapy
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Akeso
Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
This study looks at giving specific types of immune cells, called regulatory T cells and conventional T cells, to patients with blood cancers who are receiving a stem cell transplant.
- Conditions
- Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin
- Trial name
- NCT01660607
- Testing
- CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), Conventional T-Cells (Tcon)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Stanford University
Classical Hodgkin Lymphoma
Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
This study evaluates bendamustine in patients aged over 60 years with classical Hodgkin Lymphoma treated by prednisone, vinblastine and doxorubicin. 90 patients will be enrolled in this study.
- Trial name
- PVAB (NCT02414568)
- Testing
- Bendamustine, Prednisone, Vinblastine
- Where
- 40 sites in Belgium, France
- Volunteers
- 90 people
- Sponsor
- The Lymphoma Academic Research Organisation
Lymphoma
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in…
- Trial name
- NCT01390584
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Hodgkins Lymphoma
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a…
- Trial name
- NCT02603419
- Testing
- Avelumab
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
This phase II trial evaluates how well AVD (doxorubicin, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma
- Trial name
- NCT03233347
- Testing
- Brentuximab Vedotin, Dacarbazine, Doxorubicin
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Academic and Community Cancer Research United